Status:
UNKNOWN
FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
Lead Sponsor:
Fudan University
Conditions:
Liver Metastasis Colon Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases
Eligibility Criteria
Inclusion
- ECOG perfomance 0-1
- pathologically confirmed colorectal carcinoma, with RAS wild type
- inital unresectable liver metastases discussed by MDT
- prior no systemical therapy or exceed 6 months after the adjuvant chemotherapy of primary tumor surgery.
- without extraheptic metastatic lesions, except for locally controlled lung metastases (RFA or SBRT)
- adequate blood, liver and renal function
- expected survival longer than 6 months
Exclusion
- with bleeding risk
- interestinal obstruction or disease
- uncontrolled hypertension and severe heart disease
- previous severe thrombotic events
- central nervous system metastases
- accompanied with other malignant tumor
Key Trial Info
Start Date :
April 17 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT04832776
Start Date
April 17 2021
End Date
December 31 2025
Last Update
April 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Colorectal Surgery Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032